RTI Surgical said yesterday it inked a deal with Oxford Performance Materials to license its OsteoFab manufacturing platform for spinal applications.
OPM’s OsteoFab is a next-generation implant manufacturing process to build implantable medical devices layer by layer using only light and Oxpekk polymer, the Alachua, Fla.-based company said.
“We are thrilled to announce this agreement with Oxford Performance Materials. OsteoFab is an incredibly exciting technology that creates new opportunities for innovation in the spinal implant market. We look forward to working with OPM to offer our customers and their patients a new alternative for spinal implants,” RTI Surgical CEO Brian Hutchison said in a press release.
The agreement, which went into effect on Feb. 4, will allow OPM to manufacture RTI’s spinal implant designs using the OsteoFab technology, while RTI will oversee the finishing steps including packaging, marketing and distribution.
“We see RTI Surgical as a growth company in the spinal implant space. RTI is a leading developer of medical implants with a long history of putting sound science behind their products. From the outset, RTI has worked closely with us and we look forward to a lengthy and productive relationship that leverages the unique benefits of OsteoFab technology to improve patient care,” OPM CEO Scott DeFelice said in prepared remarks.